Bausch Health Companies Inc. (BHC)

The company reported its Q4 2025 results in February 2026, with a GAAP net loss of $112 million and revenues of $2.80 billion. Bausch Health is scheduled to release its Q1 2026 financial results on April 29, 2026. CABTREO was launched in Canada in October 2024, Thermage FLX received regulatory approval in Canada in April 2025, Bausch + Lomb launched its preloaded enVista Envy Full Range of Vision Intraocular Lenses in Europe in April 2026, and Solta Medical launched the Clear + Brilliant Touch Laser in Canada in February 2026. Bausch + Lomb announced positive 24-month U.S. data on the ELIOS System for the treatment of glaucoma in March 2026. Analysts have a Hold consensus rating for BHC, with an average price target of $8.33. The stock experienced fluctuations due to a Q4 EPS miss, a Barclays price target cut, and a Weiss Ratings downgrade, but also saw a surge amid broad market rallies and geopolitical de-escalation hopes.

Information regarding the specific demand seasonality for Bausch Health Cos., Inc. products and services is not explicitly detailed in the provided search results. While some sources indicate that seasonality analysis is performed for BHC stock returns, the actual seasonal patterns for product demand are not publicly available in the provided snippets.

Bausch Health Companies Inc. is a global, diversified pharmaceutical and medical device company operating primarily within the Healthcare sector. It focuses on specialty and generic drug manufacturing, as well as glasses, contact lens, and ophthalmic instrument manufacturing. The company develops, manufactures, and markets a wide array of prescription and over-the-counter pharmaceuticals, medical devices, and consumer health products. Its business is structured into segments such as Salix, International, Solta Medical, Diversified, and Bausch + Lomb, covering areas like gastroenterology, medical aesthetics, and eye health.

Bausch Health Companies Inc. has a significant global presence, manufacturing and marketing its products in over 90 countries and regions. The company serves patients and healthcare providers across North America, Europe, the Middle East, Africa, Asia Pacific, and Latin America. Its global corporate headquarters are located in Laval, Quebec, Canada, with U.S. headquarters in Bridgewater, New Jersey.

Bausch Health's brand reputation has been influenced by both positive initiatives and challenges. OraPharma partnered with Alex Rodriguez to launch its Cover Your Bases gum disease awareness campaign. Bausch Health announced the Ortho Dermatologics 2026 ASPIRE HIGHER Scholarship Program and the 2026 Gastrointestinal Health Scholars Program. A securities fraud investigation into its subsidiary, Bausch + Lomb, by the Portnoy Law Firm has created a reputational overhang for Bausch Health.

Bausch Health Companies Inc. has a diverse ownership structure, with institutional investors holding a significant portion of the shares. Key institutional shareholders include Paulson & Co. Inc., GoldenTree Asset Management LP, The Vanguard Group Inc., and others. John Paulson is identified as the largest individual shareholder. Retail investors also hold a notable portion of BHC stock.